Originally published as JCO Early Release 10.1200/JCO.2003.01.082 on July 1 2003
Journal of Clinical Oncology, Vol 21, Issue 16
(August), 2003: 3051-3059
© 2003 American Society for Clinical Oncology
Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma
John P. Leonard,
Morton Coleman,
Jamie C. Ketas,
Amy Chadburn,
Scott Ely,
Richard R. Furman,
William A. Wegener,
Hans J. Hansen,
Heather Ziccardi,
Michael Eschenberg,
Urte Gayko,
Alessandra Cesano,
David M. Goldenberg
From the Center for Lymphoma and Myeloma, Division of Hematology and Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital; New York, NY; Immunomedics, Inc, Morris Plains; Center for Molecular Medicine and Immunology; Garden State Cancer Center; Belleville, NJ; and Amgen Inc, Thousand Oaks, CA.
Address reprint requests to John P. Leonard, MD, Center for Lymphoma and Myeloma and Division of Hematology and Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 East 70th Street, New York, NY 10021; email: jpleonar{at}med.cornell.edu.
Purpose: This single-center, dose-escalation study examines the safety, efficacy, and pharmacokinetics of epratuzumab (anti-CD22 humanized monoclonal antibody) in patients with recurrent indolent non-Hodgkin’s lymphoma (NHL).
Patients and Methods: Patients had indolent NHL and recurrent disease after at least one chemotherapy regimen. Epratuzumab was administered intravenously at 120 to 1,000 mg/m2 over 30 to 60 minutes weekly for four treatments.
Results: Fifty-five patients received epratuzumab and were assessable for safety; 51 patients were assessable for response. Patients were heavily pretreated (50% had at least four prior regimens) and 49% had bulky disease ( 5 cm). Epratuzumab was well tolerated, with no dose-limiting toxicity. Circulating B cells transiently decreased without significant effects on T cells or immunoglobulin levels. More than 95% of infusions were completed in approximately 1 hour. Mean serum half-life was 23 days. Across all dose levels and histologies, nine patients (18%; 95% confidence interval, 8% to 31%) achieved objective response, including three complete responses (CRs). All responses were in patients with follicular NHL: 24% of these patients responded, including 43% in the 360 mg/m2 dose group and 27% in the 480 mg/m2 dose group. No responses were observed in other indolent histologies. Median duration of objective response was 79.3 weeks (range, 11.1 to 143.3 weeks), with median time to progression for responders of 86.6 weeks by Kaplan-Meier estimate.
Conclusion: Epratuzumab was well tolerated at up to 1,000 mg/m2/wk (for 4 weeks) and had clinical activity. One third of responding patients achieved CR. A 43% objective response rate in follicular NHL patients treated at 360 mg/m2/wk indicates that this dose should be explored in additional studies.
Supported by Immunomedics, Inc, Morris Plains, NJ, and Amgen Inc, Thousand Oaks, CA. J.P.L. is supported in part by a K23 award from the National Institutes of Health (RR16814-02), and a pilot grant from the Cornell Center for Aging Research and Clinical Care. J.P.L. has served as a consultant to Amgen. M.C., W.A.W., H.J.H., H.Z., and D.M.G. are officers and/or employees of Immunomedics, Inc. M.E., U.G., and A.C. are employees of Amgen, Inc.
This article has been cited by other articles:
|
|
|
|
 
B. D. Cheson and J. P. Leonard
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
N. Engl. J. Med.,
August 7, 2008;
359(6):
613 - 626.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Raetz, M. S. Cairo, M. J. Borowitz, S. M. Blaney, M. D. Krailo, T. A. Leil, J. M. Reid, D. M. Goldenberg, W. A. Wegener, W. L. Carroll, et al.
Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study
J. Clin. Oncol.,
August 1, 2008;
26(22):
3756 - 3762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A M Jacobi, D M Goldenberg, F Hiepe, A Radbruch, G R Burmester, and T Dorner
Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls
Ann Rheum Dis,
April 1, 2008;
67(4):
450 - 457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Qu, D. M. Goldenberg, T. M. Cardillo, V. Shi, H. J. Hansen, and C.-H. Chang
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action
Blood,
February 15, 2008;
111(4):
2211 - 2219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Rowe and A. H. Goldstone
How I treat acute lymphocytic leukemia in adults
Blood,
October 1, 2007;
110(7):
2268 - 2275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard
Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma
Clin. Cancer Res.,
September 15, 2007;
13(18):
5636s - 5642s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ramos-Casals and P. Brito-Zeron
Emerging biological therapies in primary Sjogren's syndrome
Rheumatology,
September 1, 2007;
46(9):
1389 - 1396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Maloney
Follicular NHL: From Antibodies and Vaccines to Graft-versus-Lymphoma Effects
Hematology,
January 1, 2007;
2007(1):
226 - 232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Strauss, F. Morschhauser, J. Rech, R. Repp, P. Solal-Celigny, P. L. Zinzani, A. Engert, B. Coiffier, D. F. Hoelzer, W. A. Wegener, et al.
Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
August 20, 2006;
24(24):
3880 - 3886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. T. Wong
Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities
Clin. Cancer Res.,
October 1, 2005;
11(19):
7151s - 7157s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Maloney
Immunotherapy for Non-Hodgkin's Lymphoma: Monoclonal Antibodies and Vaccines
J. Clin. Oncol.,
September 10, 2005;
23(26):
6421 - 6428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Leonard, M. Coleman, J. Ketas, M. Ashe, J. M. Fiore, R. R. Furman, R. Niesvizky, T. Shore, A. Chadburn, H. Horne, et al.
Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
August 1, 2005;
23(22):
5044 - 5051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Linden, C. Hindorf, E. Cavallin-Stahl, W. A. Wegener, D. M. Goldenberg, H. Horne, T. Ohlsson, L. Stenberg, S.-E. Strand, and J. Tennvall
Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab
Clin. Cancer Res.,
July 15, 2005;
11(14):
5215 - 5222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Leonard
Targeting CD20 in Follicular NHL: Novel Anti-CD20 Therapies, Antibody Engineering, and the Use of Radioimmunoconjugates
Hematology,
January 1, 2005;
2005(1):
335 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Sharkey and D. M. Goldenberg
Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
J. Nucl. Med.,
January 1, 2005;
46(1_suppl):
115S - 127S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Stein and D. M. Goldenberg
A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy
Mol. Cancer Ther.,
December 1, 2004;
3(12):
1559 - 1564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Stein, Z. Qu, T. M. Cardillo, S. Chen, A. Rosario, I. D. Horak, H. J. Hansen, and D. M. Goldenberg
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies
Blood,
December 1, 2004;
104(12):
3705 - 3711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, R. Furman, M. W. Schuster, E. J. Feldman, M. Ashe, S. J. Schuster, W. A. Wegener, et al.
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma: Phase I/II Clinical Trial Results
Clin. Cancer Res.,
August 15, 2004;
10(16):
5327 - 5334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Rizzieri, G. Akabani, M. R. Zalutsky, R. E. Coleman, S. D. Metzler, J. E. Bowsher, B. Toaso, E. Anderson, A. Lagoo, S. Clayton, et al.
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
Blood,
August 1, 2004;
104(3):
642 - 648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Stein, Z. Qu, S. Chen, A. Rosario, V. Shi, M. Hayes, I. D. Horak, H. J. Hansen, and D. M. Goldenberg
Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
April 15, 2004;
10(8):
2868 - 2878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Sharkey, A. Brenner, J. Burton, G. Hajjar, S. P. Toder, A. Alavi, A. Matthies, D. E. Tsai, S. J. Schuster, E. A. Stadtmauer, et al.
Radioimmunotherapy of Non-Hodgkin's Lymphoma with 90Y-DOTA Humanized Anti-CD22 IgG (90Y-Epratuzumab): Do Tumor Targeting and Dosimetry Predict Therapeutic Response?
J. Nucl. Med.,
December 1, 2003;
44(12):
2000 - 2018.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J.S. Dyer
Bioweapons of Tumor Mass Destruction?
J. Clin. Oncol.,
August 15, 2003;
21(16):
3011 - 3012.
[Full Text]
[PDF]
|
|
|
|
